Sheridan John F 4
4 · TANDEM DIABETES CARE INC · Filed Nov 19, 2025
Insider Transaction Report
Form 4
Sheridan John F
DirectorPRESIDENT & CEO
Transactions
- Exercise/Conversion
Common Stock
2025-11-17+5,982→ 120,638 total - Exercise/Conversion
Restricted Stock Unit
2025-11-17−5,982→ 35,894 total→ Common Stock (5,982 underlying) - Tax Payment
Common Stock
2025-11-17$18.61/sh−2,779$51,717→ 114,656 total - Tax Payment
Common Stock
2025-11-17$18.61/sh−3,038$56,537→ 117,600 total - Exercise/Conversion
Common Stock
2025-11-17+5,472→ 117,435 total - Exercise/Conversion
Restricted Stock Unit
2025-11-17−5,472→ 10,943 total→ Common Stock (5,472 underlying)
Footnotes (6)
- [F1]Shares withheld by Tandem Diabetes Care Inc. (the Company) to satisfy tax withholding requirements on vesting of restricted stock units (RSU). No shares were sold.
- [F2]Awarded on May 25, 2023 pursuant to the Tandem Diabetes Care Inc. 2023 Long-Term Incentive Plan, as amended, and agreements related thereto (the 2023 Plan).
- [F3]Each RSU represents a contingent right to receive either one share of common stock of the Issuer or cash in lieu thereof, at the Issuer's discretion, in accordance with the terms of the 2023 Plan.
- [F4]RSU vest as to thirty-three percent (33%) of the total number of shares subject to the RSU on 5/15/2024, and the remaining shares shall vest in eight (8) equal quarterly installments thereafter.
- [F5]Awarded on May 23, 2024 pursuant to the 2023 Plan, as amended.
- [F6]RSU vest as to thirty-three percent (33%) of the total number of shares subject to the RSU on 5/15/2025, and the remaining shares shall vest in eight (8) equal quarterly installments thereafter.